Targeting Toll-like receptors: emerging therapeutics?

[1]  J. Kline,et al.  Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. , 2010, Drug news & perspectives.

[2]  E. Pålsson-McDermott,et al.  Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21 , 2010, Nature Immunology.

[3]  M. Bolognesi,et al.  Structural basis for bivalent Smac-mimetics recognition in the IAP protein family. , 2009, Journal of molecular biology.

[4]  Konan Peck,et al.  Identification and characterization of oligonucleotides that inhibit Toll-like receptor 2-associated immune responses , 2022 .

[5]  F. Cominelli,et al.  Emerging drugs for the treatment of ulcerative colitis , 2009, Expert opinion on emerging drugs.

[6]  L. O’Neill,et al.  Recent insights into the structure of Toll-like receptors and post-translational modifications of their associated signalling proteins. , 2009, The Biochemical journal.

[7]  Lutz Hamann,et al.  Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock , 2009, Proceedings of the National Academy of Sciences.

[8]  Jorge Kalil,et al.  Heterozygosity for the S180L variant of MAL/TIRAP, a gene expressing an adaptor protein in the Toll-like receptor pathway, is associated with lower risk of developing chronic Chagas cardiomyopathy. , 2009, The Journal of infectious diseases.

[9]  A. Goodchild,et al.  Primary Leukocyte Screens for Innate Immune Agonists , 2009, Journal of biomolecular screening.

[10]  H. Gram,et al.  The critical role of kinase activity of interleukin-1 receptor-associated kinase 4 in animal models of joint inflammation. , 2009, Arthritis and rheumatism.

[11]  S. Girardin,et al.  Unleashing the therapeutic potential of NOD-like receptors , 2009, Nature Reviews Drug Discovery.

[12]  R. Xu,et al.  A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. , 2009, American Journal of Physiology - Gastrointestinal and Liver Physiology.

[13]  C. Bryant,et al.  Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer , 2009, Pharmacological Reviews.

[14]  B. Jasani,et al.  Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. , 2009, Vaccine.

[15]  John Calvin Reed,et al.  Lymphocyte-specific TRAF3 transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer. , 2009, Blood.

[16]  Y. Bossé,et al.  Polymorphisms in interleukin‐1 receptor‐associated kinase 4 are associated with total serum IgE , 2009, Allergy.

[17]  M. Netea,et al.  A Crohn's disease–associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1 , 2009, Nature Immunology.

[18]  Hayyoung Lee,et al.  The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex , 2009, Nature.

[19]  Ryan M. O’Connell,et al.  Inositol phosphatase SHIP1 is a primary target of miR-155 , 2009, Proceedings of the National Academy of Sciences.

[20]  Dong Yu,et al.  IMO-3100, an Antagonist of Toll-Like Receptors 7 and 9, Modulates Gene Expression and Regulatory Networks Induced by Ligands (48.25) , 2009, The Journal of Immunology.

[21]  P. Cohen.  Targeting protein kinases for the development of anti-inflammatory drugs. , 2009, Current opinion in cell biology.

[22]  R. Jerala,et al.  Therapeutic applications of nucleic acids as ligands for Toll-like receptors. , 2009, Current opinion in molecular therapeutics.

[23]  B. Kronenberger,et al.  Current and future treatment options for HCV. , 2009, Annals of hepatology.

[24]  M. Pallardy,et al.  TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation , 2009, Journal of leukocyte biology.

[25]  J. Kalbfleisch,et al.  Differential roles of TLR2 and TLR4 in acute focal cerebral ischemia/reperfusion injury in mice , 2009, Brain Research.

[26]  M. Feldmann.  Translating molecular insights in autoimmunity into effective therapy. , 2009, Annual review of immunology.

[27]  A. Harandi,et al.  Vaccine adjuvants: scientific challenges and strategic initiatives , 2009, Expert review of vaccines.

[28]  B. Lie,et al.  A coding polymorphism in NALP1 confers risk for autoimmune Addison's disease and type 1 diabetes , 2009, Genes and Immunity.

[29]  L. Dubuske,et al.  Significant Reduction In Combined Symptom And Medication Score Compared With Placebo Following MPL-Adjuvanted uSCIT In Patients With Seasonal Grass Pollen Allergy , 2009 .

[30]  E. Alnemri,et al.  AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA , 2009, Nature.

[31]  M. Bolognesi,et al.  Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2. , 2009, Biochemical and biophysical research communications.

[32]  D. M. van der Heijde,et al.  Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy , 2008, Annals of the rheumatic diseases.

[33]  B. Thiers.  An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma , 2009 .

[34]  M. Mason,et al.  A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. , 2009, Vaccine.

[35]  R. Medzhitov,et al.  Toll-like receptors and cancer , 2009, Nature Reviews Cancer.

[36]  M. Bianchi,et al.  Induction of inflammatory and immune responses by HMGB1–nucleosome complexes: implications for the pathogenesis of SLE , 2008, The Journal of experimental medicine.

[37]  L. O’Neill,et al.  Adding fuel to fire: microRNAs as a new class of mediators of inflammation , 2008, Annals of the rheumatic diseases.

[38]  J. Keats,et al.  Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-κB signaling , 2008, Nature Immunology.

[39]  J. Anaya,et al.  TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic lupus erythematosus. , 2008, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[40]  G. Henze,et al.  Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia. , 2008, Vaccine.

[41]  M. Murata.  Activation of Toll‐like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP‐105) sufficiently enhances immune responses against tumors , 2008, Cancer science.

[42]  T. Egeland,et al.  Polymorphisms in CLEC16A and CIITA at 16p13 are associated with primary adrenal insufficiency. , 2008, The Journal of clinical endocrinology and metabolism.

[43]  T. Griffith,et al.  Role of neutrophils in BCG immunotherapy for bladder cancer. , 2008, Urologic oncology.

[44]  Alicia P. Higueruelo,et al.  IRAK-4 inhibitors. Part III: a series of imidazo[1,2-a]pyridines. , 2008, Bioorganic & medicinal chemistry letters.

[45]  Osamu Takeuchi,et al.  Sequential control of Toll-like receptor–dependent responses by IRAK1 and IRAK2 , 2008, Nature Immunology.

[46]  Ana M. Rojas,et al.  The Nod-Like Receptor (NLR) Family: A Tale of Similarities and Differences , 2008, PloS one.

[47]  D. Davies,et al.  Structural Basis of Toll-Like Receptor 3 Signaling with Double-Stranded RNA , 2008, Science.

[48]  A. Hughes,et al.  Functional diversification of the toll-like receptor gene family , 2008, Immunogenetics.

[49]  Joseph A. DiDonato,et al.  An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models , 2008, Science.

[50]  P. Doevendans,et al.  Bridging innate immunity and myocardial ischemia/reperfusion injury: the search for therapeutic targets. , 2008, Current pharmaceutical design.

[51]  R. Vierkant,et al.  Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. , 2008, Vaccine.

[52]  J. Todd,et al.  Analysis of association of the TIRAP (MAL) S180L variant and tuberculosis in three populations , 2008, Nature Genetics.

[53]  S. Kippenberger,et al.  Clinical application of CpG-, non-CpG-, and antisense oligodeoxynucleotides as immunomodulators. , 2008, Current opinion in molecular therapeutics.

[54]  T. Parkinson.  The future of toll-like receptor therapeutics. , 2008, Current opinion in molecular therapeutics.

[55]  A. Hauschild,et al.  An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma , 2008, Clinical Cancer Research.

[56]  M. Wei,et al.  Bacterial targeted tumour therapy-dawn of a new era. , 2008, Cancer letters.

[57]  L. Zhao,et al.  Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. , 2008, The Journal of infectious diseases.

[58]  R. K. Evans,et al.  Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. , 2008, Vaccine.

[59]  Arthur M. Krieg,et al.  Toll-like receptor 9 (TLR9) agonists in the treatment of cancer , 2008, Oncogene.

[60]  I. Marinou,et al.  The Mal/TIRAP S180L and TLR4 G299D polymorphisms are not associated with susceptibility to, or severity of, rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[61]  N. Ravet,et al.  New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes. , 2007, Rheumatology.

[62]  J. Banchereau,et al.  Pyogenic Bacterial Infections in Humans with MyD88 Deficiency , 2003, Science.

[63]  J. Kline,et al.  Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. , 2008, Drug news & perspectives.

[64]  R. Coffman,et al.  Treatment of lupus‐prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms , 2007, European journal of immunology.

[65]  S. Agrawal,et al.  Synthetic agonists of Toll-like receptors 7, 8 and 9. , 2007, Biochemical Society transactions.

[66]  C. Yunis,et al.  First in Human Phase I Trial of 852A, a Novel Systemic Toll-like Receptor 7 Agonist, to Activate Innate Immune Responses in Patients with Advanced Cancer , 2007, Clinical Cancer Research.

[67]  Lars Karlsson,et al.  TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. , 2007, Inflammation & allergy drug targets.

[68]  J. Pugin,et al.  Pivotal Involvement of Fcγ Receptor IIA in the Neutralization of Lipopolysaccharide Signaling via a Potent Novel Anti-TLR4 Monoclonal Antibody 15C1* , 2007, Journal of Biological Chemistry.

[69]  F. Colland,et al.  Patented small molecule inhibitors in the ubiquitin proteasome system , 2007, BMC Biochemistry.

[70]  David L. Vaux,et al.  IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis , 2007, Cell.

[71]  C. Cooper,et al.  Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy , 2007, Expert opinion on biological therapy.

[72]  Muller Fabbri,et al.  Modulation of miR-155 and miR-125b Levels following Lipopolysaccharide/TNF-α Stimulation and Their Possible Roles in Regulating the Response to Endotoxin Shock1 , 2007, The Journal of Immunology.

[73]  Jian Huang,et al.  Toll-like receptors in inflammation, infection and cancer. , 2007, International immunopharmacology.

[74]  S. Paik,et al.  Crystal Structure of the TLR1-TLR2 Heterodimer Induced by Binding of a Tri-Acylated Lipopeptide , 2007, Cell.

[75]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[76]  Dong Yu,et al.  Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8 , 2007, Proceedings of the National Academy of Sciences.

[77]  M. Mattson,et al.  Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits , 2007, Proceedings of the National Academy of Sciences.

[78]  Charles Schmidt.  Clinical setbacks for toll-like receptor 9 agonists in cancer , 2007, Nature Biotechnology.

[79]  M. Nothnagel,et al.  Polymorphisms in NACHT‐LRR (NLR) genes in atopic dermatitis , 2007, Experimental dermatology.

[80]  C. Yunis,et al.  Pharmacokinetics of 852A, an Imidazoquinoline Toll‐Like Receptor 7‐Specific Agonist, Following Intravenous, Subcutaneous, and Oral Administrations in Humans , 2007, Journal of clinical pharmacology.

[81]  J. McHutchison,et al.  Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. , 2007, Journal of hepatology.

[82]  P. Baldrick,et al.  Pollinex® Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL®) for the treatment of ragweed pollen allergy , 2007, Journal of applied toxicology : JAT.

[83]  M. Calaza,et al.  Opposed independent effects and epistasis in the complex association of IRF5 to SLE , 2007, Genes and Immunity.

[84]  Annemarie Ledeboer,et al.  Ibudilast (AV-411) , 2007, Expert opinion on investigational drugs.

[85]  Thomas C. Mitchell,et al.  The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4 , 2007, Science.

[86]  J. Casanova,et al.  Inherited human IRAK-4 deficiency: an update , 2007, Immunologic research.

[87]  A. Aderem,et al.  A polymorphism in human TLR2 is associated with increased susceptibility to tuberculous meningitis , 2007, Genes and Immunity.

[88]  P. Viens,et al.  Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. , 2007, European journal of pharmacology.

[89]  H. Anders,et al.  Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. , 2007, Journal of the American Society of Nephrology : JASN.

[90]  F. Demirci,et al.  Association of a Common Interferon Regulatory Factor 5 (IRF5) Variant with Increased Risk of Systemic Lupus Erythematosus (SLE) , 2007, Annals of human genetics.

[91]  R. Coffman,et al.  Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists , 2007, Nature Medicine.

[92]  A. Wald,et al.  Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. , 2007, The Journal of infectious diseases.

[93]  T. Billiar,et al.  A NOVEL INHIBITORY PEPTIDE OF TOLL-LIKE RECEPTOR SIGNALING LIMITS LIPOPOLYSACCHARIDE-INDUCED PRODUCTION OF INFLAMMATORY MEDIATORS AND ENHANCES SURVIVAL IN MICE , 2007, Shock.

[94]  K. Ishii,et al.  Toll or Toll-Free Adjuvant Path Toward the Optimal Vaccine Development , 2007, Journal of Clinical Immunology.

[95]  A. Krieg.  Toll-free vaccines? , 2007, Nature Biotechnology.

[96]  C. Hogaboam,et al.  Infectious disease, the innate immune response, and fibrosis. , 2007, The Journal of clinical investigation.

[97]  Giorgio Sirugo,et al.  A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis , 2007, Nature Genetics.

[98]  M. Newman,et al.  A Phase II, Double-Blind, Placebo-Controlled, Ascending-Dose Study of Eritoran (E5564), a Lipid A Antagonist, in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass , 2007, Anesthesia and analgesia.

[99]  J. Ravetch,et al.  Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance. , 2007, Trends in immunology.

[100]  P. Hine,et al.  Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109. , 2007, Vaccine.

[101]  J. Jørgensen,et al.  Characterization of three distinct CpG oligonucleotide classes which differ in ability to induce IFN alpha/beta activity and cell proliferation in Atlantic salmon (Salmo salar L.) leukocytes. , 2007, Developmental and comparative immunology.

[102]  D. Rossignol,et al.  Influence of Plasma Cholesterol and Triglyceride Concentrations and Eritoran (E5564) Micelle Size on its Plasma Pharmacokinetics and Ex Vivo Activity Following Single Intravenous Bolus Dose Into Healthy Female Rabbits , 2007, Pharmaceutical Research.

[103]  B. Beutler,et al.  Adjuvant-Enhanced Antibody Responses in the Absence of Toll-Like Receptor Signaling , 2006, Science.

[104]  G. Storme,et al.  The radiosensitizing effect of immunoadjuvant OM-174 requires cooperation between immune and tumor cells through interferon-gamma and inducible nitric oxide synthase. , 2006, International journal of radiation oncology, biology, physics.

[105]  Kirk W. Johnson,et al.  The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. , 2006, Neuron glia biology.

[106]  I. Heijink,et al.  Strategies for targeting T-cells in allergic diseases and asthma. , 2006, Pharmacology & therapeutics.

[107]  A. Simm,et al.  E5564 (Eritoran) inhibits lipopolysaccharide-induced cytokine production in human blood monocytes , 2006, Inflammation Research.

[108]  D. Baltimore,et al.  NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses , 2006, Proceedings of the National Academy of Sciences.

[109]  Doo-sik Kim,et al.  A combination of E. coli DNA fragments and modified lipopolysaccharides as a cancer immunotherapy. , 2006, Vaccine.

[110]  J. Wade Harper,et al.  Drug discovery in the ubiquitin–proteasome system , 2006, Nature Reviews Drug Discovery.

[111]  L. O’Neill,et al.  Targeting signal transduction as a strategy to treat inflammatory diseases , 2006, Nature Reviews Drug Discovery.

[112]  Judy H Cho,et al.  Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[113]  S. Ménard,et al.  Antitumor Activity of the TLR-5 Ligand Flagellin in Mouse Models of Cancer1 , 2006, The Journal of Immunology.

[114]  S. Lebecque,et al.  TLR3 Can Directly Trigger Apoptosis in Human Cancer Cells1 , 2006, The Journal of Immunology.

[115]  O. Hazeki,et al.  A Novel Cyclohexene Derivative, Ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), Selectively Inhibits Toll-Like Receptor 4-Mediated Cytokine Production through Suppression of Intracellular Signaling , 2006, Molecular Pharmacology.

[116]  A. Shaw,et al.  Triggering TLR signaling in vaccination. , 2006, Trends in immunology.

[117]  S. Akira,et al.  TLR signaling. , 2006, Current topics in microbiology and immunology.

[118]  Dan L. Nicolae,et al.  Dominant-negative TLR 5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn ’ s disease , 2006 .

[119]  D. Schwartz,et al.  Polymorphisms of the Toll-like receptors and human disease. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[120]  Noel T. Whelan,et al.  Innate immunity for biodefense: A strategy whose time has come , 2005, Journal of Allergy and Clinical Immunology.

[121]  H. Gascan,et al.  Direct Stimulation of Human T Cells via TLR5 and TLR7/8: Flagellin and R-848 Up-Regulate Proliferation and IFN-γ Production by Memory CD4+ T Cells1 , 2005, The Journal of Immunology.

[122]  D. Schwartz,et al.  Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[123]  N. Klopp,et al.  Association of NOD1 polymorphisms with atopic eczema and related phenotypes. , 2005, The Journal of allergy and clinical immunology.

[124]  S. Grelli,et al.  Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions. , 2005, International immunopharmacology.

[125]  S. Momohara,et al.  Single nucleotide polymorphisms in the gene encoding the major histocompatibility complex class II transactivator (CIITA) in systemic lupus erythematosus , 2005, Annals of the rheumatic diseases.

[126]  D. Jewell,et al.  Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. , 2005, Human molecular genetics.

[127]  D. Persing,et al.  Synthetic Toll-Like Receptor 4 Agonists Stimulate Innate Resistance to Infectious Challenge , 2005, Infection and Immunity.

[128]  D. Trune,et al.  Identification of a Peptide Derived from Vaccinia Virus A52R Protein That Inhibits Cytokine Secretion in Response to TLR-Dependent Signaling and Reduces In Vivo Bacterial-Induced Inflammation1 , 2005, The Journal of Immunology.

[129]  J. Rivers,et al.  Imiquimod 5% cream for the treatment of actinic keratoses. , 2005, Skin therapy letter.

[130]  T. Ruzicka,et al.  Gene expression in actinic keratoses: pharmacological modulation by imiquimod , 2004, The British journal of dermatology.

[131]  W. Sterry,et al.  Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. , 2004, Archives of dermatology.

[132]  W. Goldman,et al.  Microbial Factor-Mediated Development in a Host-Bacterial Mutualism , 2004, Science.

[133]  E. Verrier,et al.  Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. , 2004, The Journal of thoracic and cardiovascular surgery.

[134]  R. Ulevitch.  Therapeutics targeting the innate immune system , 2004, Nature Reviews Immunology.

[135]  J. Casanova,et al.  Interleukin receptor-associated kinase (IRAK-4) deficiency associated with bacterial infections and failure to sustain antibody responses. , 2004, The Journal of pediatrics.

[136]  M. Guenounou,et al.  Toll-like receptors and immune response in allergic disease , 2004, Clinical reviews in allergy & immunology.

[137]  L. Klareskog,et al.  Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial , 2004, The Lancet.

[138]  P. Payette,et al.  Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities , 2004, European journal of immunology.

[139]  D. Kuhns,et al.  Distinct Mutations in IRAK-4 Confer Hyporesponsiveness to Lipopolysaccharide and Interleukin-1 in a Patient with Recurrent Bacterial Infections , 2003, The Journal of experimental medicine.

[140]  A. Al-ghonaium,et al.  Pyogenic Bacterial Infections in Humans with IRAK-4 Deficiency , 2003, Science.

[141]  F. Gusovsky,et al.  Inhibition of Endotoxin Response by E5564, a Novel Toll-Like Receptor 4-Directed Endotoxin Antagonist , 2003, Journal of Pharmacology and Experimental Therapeutics.

[142]  I. Haga,et al.  The Poxvirus Protein A52R Targets Toll-like Receptor Signaling Complexes to Suppress Host Defense , 2003, The Journal of experimental medicine.

[143]  G. Cooke,et al.  Toll-like receptor 4 polymorphisms and atherogenesis. , 2002, The New England journal of medicine.

[144]  Douglas T. Golenbock,et al.  Lipopolysaccharide Rapidly Traffics to and from the Golgi Apparatus with the Toll-like Receptor 4-MD-2-CD14 Complex in a Process That Is Distinct from the Initiation of Signal Transduction* 210 , 2002, The Journal of Biological Chemistry.

[145]  S. Calvano,et al.  Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. , 2002, The Journal of infectious diseases.

[146]  S. Akira,et al.  Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway , 2002, Nature Immunology.

[147]  P. Godowski,et al.  Tissue Expression of Human Toll-Like Receptors and Differential Regulation of Toll-Like Receptor mRNAs in Leukocytes in Response to Microbes, Their Products, and Cytokines , 2002, The Journal of Immunology.

[148]  Judy H. Cho,et al.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease , 2001, Nature.

[149]  J. Mira,et al.  A Novel Polymorphism in the Toll-Like Receptor 2 Gene and Its Potential Association with Staphylococcal Infection , 2000, Infection and Immunity.

[150]  R. Dziarski,et al.  Role of MD-2 in TLR2- and TLR4-mediated recognition of Gram-negative and Gram-positive bacteria and activation of chemokine genes , 2000 .

[151]  R. Dziarski,et al.  Role of MD-2 in TLR2- and TLR4-mediated recognition of Gram-negative and Gram-positive bacteria and activation of chemokine genes. , 2000, Journal of endotoxin research.

[152]  C. Janeway,et al.  The Toll receptor family and microbial recognition. , 2000, Trends in microbiology.

[153]  P. Allavena,et al.  Differential Expression and Regulation of Toll-Like Receptors (TLR) in Human Leukocytes: Selective Expression of TLR3 in Dendritic Cells1 , 2000, The Journal of Immunology.

[154]  A. Aderem,et al.  The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens , 1999, Nature.

[155]  L. Manzel,et al.  Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. , 1998, Journal of immunology.

[156]  O. Weiland,et al.  Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. , 1997, Journal of hepatology.

[157]  N. Sobol,et al.  Preliminary results , 2020, Asymptotic Analysis of Random Walks: Light-Tailed Distributions.